Endocrinology News and Research

Latest Endocrinology News and Research

IMUSA invites community to take advantage of free diabetes screenings, healthy diabetes-friendly recipes

IMUSA, the leading brand of Hispanic housewares in North America, in conjunction with The American Diabetes Association and local health organizations, invite the community to take advantage of free diabetes screenings, meet and greet popular Hispanic Chef Elsie Ramos, and sample healthy diabetes-friendly recipes.

10 Aug 2010

Penwest Pharmaceuticals signs merger agreement with Endo Pharmaceuticals

Penwest Pharmaceuticals Co. today announced that it has entered into a merger agreement under which its long-time partner in the development and commercialization of Opana ER, Endo Pharmaceuticals, has agreed to acquire all of the common stock of Penwest for $5.00 per share in cash. The total equity value of the transaction is approximately $168 million.

10 Aug 2010

Older Americans suffer from full-blown depression: Report

Maureen Duffy's memories of her grandmother are cloudy. Not because of time, but by a condition that cast a shadow over the woman Duffy had visited as a child.

10 Aug 2010

CGI receive contract for chronic disease management system

eHealth Ontario and Infrastructure Ontario announced today that with the awarding of a contract to CGI Information Systems and Management Consultants Inc., a subsidiary of CGI Group Inc., work can begin on a chronic disease management system (CDMS) that will be used initially as a Diabetes Registry to manage diabetes care.

10 Aug 2010

Array BioPharma fiscal 2010 revenue increases to $53.9 million

Array BioPharma Inc. today reported financial results for the fourth quarter and full year of fiscal 2010.

10 Aug 2010

Mild sleep restriction for several nights can affect cognitive tasks: Research

Many people are sleep restricted, either because they have to or because they choose to be, she says. "Instead of going to bed when they are tired, like they should, people watch TV and want to have an active social life," she says. "People count on catching up on their sleep on the weekends, but it may not be enough."

10 Aug 2010

Endo to acquire Penwest for $5.00 per share

Endo Pharmaceuticals today announced actions designed to advance the company's leadership and growth in pain management, including an agreement to acquire all outstanding shares of Penwest Pharmaceuticals for $5.00 in cash per share, or an estimated enterprise value of approximately $144 million at the time of deal close. Penwest has been working with Endo since 1997 on the development and commercialization of OPANA® ER and receives a royalty stream on net sales of the product.

10 Aug 2010

Researchers find disparities among children suffering from repeated ear infections

Research has documented that ethnic and socioeconomic disparities exist among patients with conditions such as heart disease and diabetes. Now, a new study by researchers from UCLA and Harvard University has found disparities among children suffering from repeated ear infections. The findings, published in the August edition of the journal Laryngoscope, show that frequent ear infections plague white children and children living below the poverty level more than children of other racial or ethnic backrounds or income levels.

10 Aug 2010

New insight into protein transport mechanism can improve chemotherapy treatments

A new study conducted in the department of Biochemistry and Molecular Biology at Tel Aviv University (TAU) elucidates the way in which toxic, yet essential, copper ions enter human cells. As a chemotherapy drug presumably enters the cells in a similar manner, the results of this study pave the way for the development of improved chemotherapeutic drugs. The groundbreaking work was published in the leading American scientific journal PNAS (Proceedings of the National Academy of Sciences).

10 Aug 2010

New microchip technology to detect oral cancer

A new test for oral cancer, which a dentist could perform by simply using a brush to collect cells from a patient's mouth, is set to be developed by researchers at the University of Sheffield and Sheffield Teaching Hospitals NHS Foundation Trust.

10 Aug 2010

Pluristem's PLacental eXpanded cell therapy effective against neuropathic and inflammatory nerve pain

Pluristem Therapeutics Inc. today announced the results of two separate pre-clinical studies in animal models which demonstrated that its PLacental eXpanded (PLX) cell therapy may be an effective treatment for both neuropathic and inflammatory nerve pain. These animal studies were conducted in collaboration with the Berlin-Brandenburg Center for Regenerative Therapies (BCRT) and the Department of Anesthesiology and Operative Intensive Care Medicine, both at the Charité-Universitätsmedizin of Berlin, Germany.

10 Aug 2010

Scientists suggest daily intake of vitamin D helps to reduce disease frequency

Anthony Norman, a leading international expert in vitamin D, proposes worldwide policy changes regarding people's vitamin D daily intake amount in order to maximize the vitamin's contribution to reducing the frequency of many diseases, including childhood rickets, adult osteomalacia, cancer, autoimmune type-1 diabetes, hypertension, cardiovascular disease, obesity and muscle weakness.

10 Aug 2010

Repros Therapeutics second-quarter net loss decreases to $1.3 million

Repros Therapeutics Inc. today announced financial results for the second quarter ended June 30, 2010.

10 Aug 2010

Bellus Health reports net loss of $5.8M for second-quarter vs. net income of $14.27M for previous year

BELLUS Health Inc. reported today its financial results for the second quarter ended June 30, 2010. The Company also announced new initiatives to reduce its annual expenditures ("burn rate") by focusing its efforts on existing products and on supporting current and future strategic partnerships. All currency figures reported in this press release, including comparative figures, are in Canadian dollars, unless otherwise specified.

9 Aug 2010

Isis second-quarter pro forma net operating loss increases to $15.5 million

Isis Pharmaceuticals, Inc. today announced its financial results for the quarter ended June 30, 2010. The Company finished the second quarter of 2010 with a pro forma net operating loss (NOL) of $15.5 million and $17.1 million for the three and six months ended June 30, 2010, respectively, compared to a pro forma net operating loss of $1.3 million and pro forma net operating income of $798,000 for the same periods of 2009.

9 Aug 2010

Lexicon Pharmaceuticals updates key progress in clinical pipeline

Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a biopharmaceutical company focused on discovering and developing breakthrough treatments for human disease, today updated the progress of its drug development programs and reported financial results for the three and six months ended June 30, 2010.

9 Aug 2010

Remote monitoring of chronic heart failure patients can reduce pressure on resources

Providing patients with chronic heart failure access to remote monitoring, for example by telephone or telemonitoring using wireless technology, reduces deaths and hospitalisations and may provide benefits on health care costs and quality of life. These are the conclusions of a new Cochrane Systematic Review by an international team of researchers.

9 Aug 2010

Apte wins Elkeles Prize for outstanding scientist in field of medicine

Ben-Gurion University of the Negev (BGU) Professor Ron N. Apte has been awarded the 2010 Samuel and Paula Elkeles Prize for Outstanding Scientist in the Field of Medicine.

9 Aug 2010

Researchers examine differences in eating habits of African Americans

Researchers looking for differences in eating habits of African Americans based on whether or not they had Type 2 diabetes uncovered an unexpected result: No matter what the blood sugar level was, the dietary intakes were pretty much the same.

7 Aug 2010

Orexigen second-quarter net loss decreases to $11.9 million

Orexigen® Therapeutics, Inc., a biopharmaceutical company focused on the treatment of obesity, today announced financial results for the second quarter of 2010. For the quarter ended June 30, 2010, Orexigen reported a net loss of $11.9 million, or $0.25 per share attributable to common stockholders, as compared to a net loss of $17.8 million, or $0.51 per share attributable to common stockholders, for the second quarter of 2009.

7 Aug 2010